G1 Therapeutics Stock Target Price and Analyst Consensus
| GTHX Stock | USD 4.28 0.20 4.90% |
The current analyst and expert consensus on G1 Therapeutics is Buy, with 2 strong buy opinions. The current projected G1 Therapeutics target price consensus is 9.50 with 6 analyst opinions. The most common way G1 Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview G1 Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on G1 Therapeutics. We strongly encourage you to use your own analysis of G1 Therapeutics to validate this buy or sell advice. G1 Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected G1 Therapeutics target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on G1 Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.
Lowest Forecast 8.65 | Highest Forecast 10.55 | Target Price 9.5 |
GTHX |
It's important to approach G1 Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
G1 Therapeutics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GTHX target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. G1 Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Buy |
Most GTHX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand GTHX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of G1 Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationG1 Therapeutics Target Price Projection
G1 Therapeutics' current and average target prices are 4.28 and 9.50, respectively. The current price of G1 Therapeutics is the price at which G1 Therapeutics is currently trading. On the other hand, G1 Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
G1 Therapeutics Market Quote on 18th of April 2024
Target Price
Analyst Consensus On G1 Therapeutics Target Price
G1 Therapeutics Analyst Ratings
G1 Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about G1 Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of G1 Therapeutics' financials, market performance, and future outlook by experienced professionals. G1 Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize G1 Therapeutics price targets
G1 Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using G1 Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at G1 Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if G1 Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional G1 Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of G1 Therapeutics is a key component of G1 Therapeutics valuation and have some predictive power on the future returns of a G1 Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of G1 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Investor Favorites Invested over 70 shares | |
 | Chemicals Invested over 40 shares | |
Check out Macroaxis Advice on G1 Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
The data published in G1 Therapeutics' official financial statements usually reflect G1 Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of G1 Therapeutics. For example, before you start analyzing numbers published by GTHX accountants, it's critical to develop an understanding of what G1 Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of G1 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, G1 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in G1 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of G1 Therapeutics. Please utilize our Beneish M Score to check the likelihood of G1 Therapeutics' management manipulating its earnings.